2026-10-30 00:39:57 UTC#541987updateconfirmednews
DaVita (DVA) stock news
DaVita (DVA) stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-10-29 22:31:11 UTC#541498duplicateconfirmednews
DaVita Inc. reports Q3 2026 adjusted EPS of $3.40, missing analyst consensus of $3.61
2026-10-29 22:24:54 UTC#541453newconfirmednews
DaVita (DVA) reports Q3 adjusted operating income of $561M, narrows FY26 guidance amid cost headwinds
2026-10-29 20:13:43 UTC#540462newconfirmeddata release
DaVita Q3 2026 Non-GAAP EPS $3.82 beats by $0.25, Revenue $3.57B beats by $50M
2026-10-29 20:05:00 UTC#540384newconfirmedpress release
DaVita Inc. reports Q3 2026 consolidated revenues of $3.578 billion
2026-10-20 16:57:32 UTC#487896newreportednews
DaVita and Fresenius shares decline on reports of planned dialysis market reforms by RFK Jr.
seeking alphaimportance 0.60trust 0.50DaVita Inc. -0.60Fresenius SE & Co. KGaA -0.60Robert F. Kennedy Jr. -0.40
2026-10-19 21:37:00 UTC#483321newconfirmedpress release
DaVita Inc. to report Q3 2026 financial results on October 29, 2026
2026-09-05 15:05:57 UTC#271891newconfirmednews
Healthcare August Recap: Moderna Gains 156% Amid Biotech Strength, DaVita Declines
2026-08-31 20:48:00 UTC#245162duplicateconfirmednews
Moderna Leads S&P 500 August Gains With 156% Surge Following Cancer Vaccine Trial Results
dow_jonesimportance 0.30trust 0.80Moderna, Inc. +0.80Merck & Co., Inc. +0.50Palantir Technologies Inc. +0.30+2 entities
2026-08-25 11:47:26 UTC#217139duplicateconfirmednews
DaVita and Humana announce value-based care partnership for chronic kidney disease patients
2026-08-25 10:00:00 UTC#216575newconfirmedpress release
DaVita and Humana expand value-based care partnership for Medicare Advantage patients with CKD
2026-08-07 13:25:00 UTC#145167newconfirmednews
Truist Securities maintains Hold on DaVita (DVA), cuts price target to $215 from $250
2026-08-05 10:20:18 UTC#128901newconfirmednews
DaVita Inc. average analyst price target raised to $230, implying 1% upside
2026-08-05 01:11:26 UTC#126816updateconfirmednews
DaVita sets 2026 midpoint guidance at $2.2B adjusted operating income and $14.65 EPS with HD rollout
2026-08-04 22:44:14 UTC#126339updateconfirmednews
DaVita Q2 revenue per treatment falls to $415.87 on lower enrollment; annual profit forecast reaffirmed
2026-08-04 22:41:18 UTC#126375duplicateconfirmednews
DaVita Q2 results meet expectations as volume growth offsets mix headwinds; FY guidance reaffirmed
2026-08-04 20:23:27 UTC#125423duplicateconfirmednews
DaVita Q2 Non-GAAP EPS $4.02 beats by $0.14, Revenue $3.55B beats by $60M
2026-08-04 20:22:40 UTC#125402newconfirmednews
DaVita Q2 earnings beat estimates on higher rates; 2026 adjusted EPS guidance set at $14.10 to $15.20
2026-08-03 16:50:45 UTC#118091newforecastanalysis
DaVita Inc. Q2 2026 Earnings Preview
2026-07-21 21:00:00 UTC#59899newconfirmedpress release